Veralto Director Cindy Wallis-Lage Receives Restricted Stock Units and Director Options in July 2026 Compensation Grant

Director Equity Compensation Structure at Veralto

Veralto Corporation, a diagnostics and life sciences technology company, maintains a standard director compensation framework that includes both equity awards and cash components. The company's board compensation approach is designed to align director interests with shareholder returns over multi-year periods. Director compensation programs in the life sciences sector typically combine immediate incentive value through options with longer-term equity exposure through restricted stock units.

Cindy L. Wallis-Lage serves as a director at Veralto and maintains her residence at the company's headquarters address in Waltham, Massachusetts. The company's board compensation practices reflect industry standards for non-employee directors at publicly traded technology and diagnostics firms. Director equity awards are commonly used across the sector to encourage board members to maintain vested interests in long-term company performance and strategic outcomes.

Restricted Stock Unit Grant Terms and Vesting Schedule

The restricted stock units granted to Director Wallis-Lage total 1,009 shares and are subject to a dual-trigger vesting mechanism. The units vest on the earlier of two dates: the first anniversary of the grant date in July 2027, or immediately prior to the next annual meeting of Veralto's shareholders following the grant date. This structure ensures that the director receives vesting credit either upon completion of a full year of service or at the annual shareholder meeting, whichever occurs first.

A significant feature of these restricted stock units is the deferred issuance of underlying shares. Rather than receiving the shares upon vesting, the actual delivery of the common stock is postponed until either the director's death or the first date of the seventh month following the director's retirement from Veralto's Board. This deferral mechanism is designed to extend the director's economic interest in the company beyond the vesting date and to encourage ongoing board engagement. Following the July 15, 2026 transaction, Director Wallis-Lage's total beneficial ownership of restricted stock units reached 3,380 shares held in direct ownership form.

Director Stock Option Award and Exercise Parameters

Director Wallis-Lage received 3,553 director stock options as part of her July 15, 2026 compensation package. These options carry a strike price of $91 per share and were fully vested as of the grant date, meaning the director has immediate exercise rights without additional service requirements. The ten-year exercise window extends from July 15, 2026, through July 15, 2036, providing an extended period during which the director may convert options into common stock at the fixed strike price.

The immediate vesting of director stock options reflects common board compensation practices designed to provide directors with prompt incentive value. By contrast with restricted stock units, which tie value to continued board service or shareholder meeting participation, fully vested options provide directors with discretionary exercise timing based on market conditions and individual financial planning. Following the transaction, Director Wallis-Lage's total beneficial ownership of director stock options increased to 9,413 shares, indicating accumulated option holdings from prior compensation periods.

Veralto's Business Operations and Market Position

Veralto Corporation operates in the diagnostics and life sciences technology sector, serving customers in healthcare, environmental monitoring, and industrial end markets. The company's portfolio spans molecular diagnostics, point-of-care testing, water and food testing, and related life sciences instrumentation. Veralto's revenue model centers on recurring consumables, instrumentation placements, and service offerings across these diagnostic platforms.

The company maintains significant scale within the life sciences diagnostics industry, with operations spanning multiple geographic regions and customer verticals. Director equity compensation at Veralto reflects the company's need to attract and retain experienced board members capable of overseeing complex technology development, regulatory compliance, and market expansion strategies. The diagnostics sector presents ongoing opportunities and challenges related to clinical adoption, reimbursement policies, and technological innovation cycles that require sophisticated board-level oversight.

Regulatory Filing Requirements and Section 16 Reporting

The transaction disclosed by Director Wallis-Lage is subject to Section 16 of the Securities Exchange Act of 1934, which requires officers, directors, and beneficial owners of more than ten percent of a company's equity to report changes in ownership. The announcement indicates that Director Wallis-Lage is currently subject to Section 16 reporting obligations and does not qualify for exemption under the "no longer subject to Section 16" provision. This classification confirms her status as a director with ongoing beneficial ownership reporting responsibilities.

The Form 4 announcement was filed by James Tanaka, acting as attorney-in-fact for Director Wallis-Lage, on July 17, 2026, two business days following the transaction date of July 15, 2026. This timing complies with SEC deadlines for beneficial ownership change reporting. The announcement provides detailed transaction codes, security descriptions, and vesting terms that allow investors and market participants to assess the nature and economic substance of director compensation arrangements at Veralto.

Direct Ownership Structure and Beneficial Ownership Position

All securities acquired by Director Wallis-Lage in the July 15, 2026 transaction are held in direct beneficial ownership form, meaning the director holds title to the securities in her own name without intervening entities or arrangements. Direct ownership is the standard structure for director equity compensation and distinguishes from indirect ownership through family entities, trusts, or other holding vehicles. The direct ownership designation indicates that the director has personal control over the timing and manner of any future disposition of the securities.

Following the July 15, 2026 transactions, Director Wallis-Lage's total beneficial ownership position includes 3,380 shares of restricted stock units and 9,413 director stock options, all held directly. This ownership level reflects director compensation accumulation over multiple grant cycles and represents a material director stake in Veralto's equity. The director's beneficial ownership creates ongoing financial alignment with shareholder interests in company performance and strategic execution.

Compensation Award Pricing and Valuation Considerations

The restricted stock units granted on July 15, 2026 were issued with no stated purchase price ($0), which is typical for equity awards issued as compensation rather than through direct purchase. The director stock options carry a strike price of $91 per share, representing the reference price for the equity award on the grant date. This strike price establishes the threshold at which the director would realize economic gain upon exercise relative to market prices prevailing at future exercise dates.

Director compensation arrangements in the life sciences sector are typically valued at grant date fair value based on closing share prices and option valuation models. The announcement does not disclose the grant date fair value assigned to these awards for accounting or tax purposes, nor does it indicate the closing share price of Veralto common stock on July 15, 2026. The immediate share price impact was not clear from available public information. Investors may reference Veralto's proxy statement for complete fair value disclosures related to director compensation for the 2026 fiscal period.

Board Composition and Director Retention Strategy

Director equity compensation programs serve as a retention and recruitment mechanism for qualified board members at public companies. Veralto's issuance of restricted stock units and director options to an existing director reflects the company's strategy to maintain board continuity and align director economic interests with long-term shareholder value creation. Equity-based director compensation typically comprises a material component of total director compensation packages at mid-cap and large-cap public companies.

The vesting and exercise parameters embedded in Veralto's director compensation structure create incentives for continued board engagement beyond the initial grant year. The deferred issuance feature of the restricted stock units, which ties share delivery to retirement or death events, extends the director's financial interest in the company across extended time horizons. This approach encourages directors to maintain involvement in company strategy and decision-making through multiple board cycles and strategic planning iterations.

Market Implications and Investor Considerations

Director equity transactions provide investors with transparency regarding board compensation practices and director confidence in long-term company prospects. When directors receive significant equity awards or exercise existing options, market observers may interpret these actions as indicators of director conviction regarding company valuation and strategic direction. The acceptance of restricted stock units subject to vesting requirements and deferred share issuance suggests director willingness to maintain extended economic exposure to Veralto.

Investors monitoring Veralto's corporate governance practices may track director equity holdings as part of broader assessment of board alignment with shareholder interests. The accumulation of director option and restricted stock unit positions over multiple compensation cycles reflects director participation in the company's long-term incentive architecture. Changes in director equity ownership or compensation structures disclosed through Form 4 announcements can provide context for evaluating board dynamics, retention stability, and management confidence in company prospects.